AzTrials
AzTrials

Eating DisordersNCT02829645

Evaluation of the Clinical, Neuropsychological and Psychosocial Situation of Patient With Eating Disorders.

A study testing Clinical assessment in people with Eating Disorders, run by University Hospital, Montpellier.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Eating disorders (ED) are serious mental illnesses with an excess mortality and many affects in the quality of life of patients and thier relatives. Management of ED is very difficult : the prognosis remains relatively poor both in terms of remission rate and quality of life. Read more about this study

Who is it for?
Ages 15 to 65 years
Conditions the study is for
Eating Disorders
What is being tested?
Clinical assessment
Could I receive a placebo?
No, everyone receives an active treatment
How many people
370 participants
Where
No sites listed yet
Study dates
Feb 2012to Oct 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • respond to DSM 4 criteria for ED
  • Age 15 to 65 years
  • Signing an informed consent.
  • Affiliated to a social security scheme or being the beneficiary of such a scheme.

Who cannot join

  • Manifest inability of the subject to understand / perform clinical and neuropsychological evaluations and tasks
  • Major protected by law (guardianship)
  • Privation of liberty by judicial or administrative decision
  • Pregnant or lactating women

About this study

Eating disorders (ED) are serious mental illnesses with an excess mortality and many affects in the quality of life of patients and thier relatives. Management of ED is very difficult : the prognosis remains relatively poor both in terms of remission rate and quality of life. In this context, the contribution of new strategies for pathophysiological exploration and the development of therapeutic options are crucial.

In this project the investigators aim to constitute un cohort of patients from a day unit specialized in the management of ED. A prospective follow-up will be offered to patients to assess their clinical and psycho-social evolution. The overall objective is to identify which factors are prognostic of clinical improvement of the ED. We also want to better characterize patients that will migrate from diagnosis to another.

Read the detailed description

The investigators propose to assess, with a cohort of patients with ED the prognostic value of cognitive abnormalities associated with ED (cognitive flexibility and central coherence) They will recruit 370 patients suffering from a current ED (anorexia, bulimia, binge eating disorder, Eating disorder not otherwise specified).

Each patient will be reassessed every year for 3 years.

Being tested
Clinical assessment
Keywords
eating disoders, neuropsychology, pronostic
Medical subject headings
Feeding and Eating Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Clinical assessmentOther

    Clinical assessment with questionnaires

Study groups in NCT02829645
Study groupRoleWhat they receive
Eating disordersOtherNot described
Receives: Other: Clinical assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Frequency of remission rates

    study of remission rates frequency at 12 months depending on the Brixton score assessed at baseline (assessment of cognitive flexibility). Remission is defined as disappearance of ED Diagnostic and Statistical Manual (DSM) criteria.

    Measured: At the inclusion and at 12, 24 and 36 months

Secondary outcomes (3)
  1. score to another neuropsychological test (Iowa gambling task (IGT)

    Study of remission rates frequency at 12 months depending on the IGT score (decision making) assessed at baseline

    Measured: At the inclusion and at 12, 24 and 36 months

  2. scores to another other neuropsychological test : Rey-Osterrieth complex figure

    Study of remission rates frequency at 12 months depending on the Rey figure assessed at baseline

    Measured: At the inclusion and at 12, 24 and 36 months

  3. scores to another neuropsychological test : D2 test of attention

    Study of remission rates frequency at 12 months depending on the D2 test (attention) assessed at baseline

    Measured: At the inclusion and at 12, 24 and 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jul 2016 (estimated)
  2. Study startFeb 2012
  3. Primary completionOct 2014
  4. Study completionOct 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
370 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02829645
Sponsor's protocol ID
UF 8854
Status last verified
Jul 2016
First submitted
7 Jul 2016
Last updated
12 Jul 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Clinical assessment in people with Eating Disorders, run by University Hospital, Montpellier.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Frequency of remission rates (time frame: At the inclusion and at 12, 24 and 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in